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Screening for depression in primary careis an issue that is highly contentious andhotly debated, and recommendations
have evolved over time. For example, early pol-
icy statements from the 1990s in Canada1 and
the United States2 recommended against screen-
ing for depression in primary care1 or did not
find enough evidence to recommend either for
or against it.2 Later, in 2002 in the US3 and in
2005 in Canada,4 recommendations were made
to screen adults for depression in primary care
settings when integrated, staff-assisted systems
for assessing and managing depression were
available. These “collaborative care” programs
typically involve multifaceted systems with
central roles for nonmedical specialists, such as
case managers, who work with primary care
physicians, mental health specialists and others
to provide management and follow-up.5
In 2009, an updated statement from the
United States Preventive Services Task Force6
reiterated the recommendation that primary care
physicians screen patients for depression in the
context of integrated systems for managing the
condition, but not where such resources are
unavailable. In contrast to this position, a 2010
guideline for depression management from the
United Kingdom’s National Institute for Health
and Clinical Excellence noted a lack of evidence
that depression screening would benefit patients
and did not recommend routine screening in pri-
mary care settings.7 Critical reflection on key
differences in these two recent recommenda-
tions is important, both for physicians who must
decide whether to screen their patients and for
developers of guidelines, such as the Canadian
Task Force on Preventive Health Care, which is
currently reviewing evidence for an updated re c -
ommendation statement. Thus, we critiqued
recent recommendations on screening for de -
pression in primary care in the context of cur-
rent evidence.
What is screening and when
should it be recommended?
In the context of depression, the word “screening“
has sometimes been used inaccurately to character-
ize a range of activities, including the use of self-
report questionnaires to track the se verity of symp-
toms and the effects of treatment, to detect relapse
among patients in which de pression has already
been detected and treated or to inform clinical con-
sultations provided to all pa tients regardless of
their scores on such questionnaires.8 None of these
activities, however, con stitutes screening. Rather,
consistent with standard definitions, screening for
depression in volves the use of questionnaires con-
cerning the symptoms of depression or small sets
of questions about depression to identify patients
who may have depression but who have not sought
treatment and whose depression has not already
been recognized by health care providers.9,10 Pa -
tients identified as possibly having depression need
further assessment and, if appropriate, should be
offered treatment.
Screening for depression is potentially useful
only to the extent that it improves patient out-
comes beyond those of standard care. Thus, to be
successful, a screening program must identify a
substantial number of patients in whom depres-
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• Screening for depression in primary care is recommended in the United
States and Canada under certain conditions, but not in the United
Kingdom.
• No trials have found that patients who undergo screening have better
outcomes than patients who do not when the same treatments are
available to both groups.
• Existing rates of treatment, high rates of false-positive results, small
treatment effects and the poor quality of routine care may explain the
lack of effect seen with screening.
• Developers of future guidelines should require evidence of benefit
from randomized controlled trials of screening, in excess of harms and
costs, before recommending screening.
Key points
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sion has not already been diagnosed, engage
those patients in treatment and obtain sufficiently
positive results to justify the costs and potential
harms associated with the program. Potential
harms from routine screening for depression are
rarely made explicit, but they include the treat-
ment of depression in patients who are incor-
rectly identified as having the disorder, the treat-
ment of mild symptoms that would often resolve
without intervention and, perhaps most impor-
tantly, the diversion of scarce resources from
other endeavours, such as ensuring better care
for patients already identified as having depres-
sion. Indeed, the poor quality of routine care for
patients with depression in primary care is well-
documented. Many patients who are given pre-
scriptions for antidepressant medications stop
taking the drugs shortly after treatment begins,
and only 20%–30% of people whose depression
is treated exclusively in a primary care setting
receive adequate care and follow-up.11,12
A number of well-established criteria should
be met before screening is recommended.13,14
Generally, it is reasonable to consider screening
when the condition in question is important and
prevalent, can be effectively treated and cannot be
readily detected without screening. Furthermore,
screening methods should be accurate and carry a
tolerably small risk of false-positive re sults. Such
results could lead to unnecessary diagnostic test-
ing, adverse effects and costs of inappropriate
treatment, as well as the sequelae of being incor-
rectly labelled (e.g., stigma). False reassurance
for false-negative results may also require consid-
eration in some circumstances. Ideally, benefits in
excess of potential harms should be consistently
shown in well-conducted, randomized, controlled
trials with sufficiently long follow-up to see
important patient -oriented outcomes.
Guidelines from the National
Institute for Health and Clinical
Excellence
The 2010 guideline statement of the National
Institute for Health and Clinical Excellence7
focused on a number of serious concerns about
routine screening for depression.15,16 These con-
cerns included the high rate of false-positive
results (often more than 50%) returned by
screening tools,17 the lack of empirical evidence
of benefit to patients, the likelihood that most
people identified only by screening would have
relatively mild symptoms of depression and
often recover without formal intervention, the
high cost and large number of resources involved
in identifying people who might gain little in
terms of improvements to their mental health18
and the diversion of re sources away from people
with more serious cases of depression whose
care is already often inadequate.
Instead of screening, the guidelines recom-
mended that physicians be alert to possible de -
pression, particularly when there is a previous
history of the condition or when patients have a
chronic physical health problem with functional
impairment, and that they ask about symptoms
of depression when there is a specific  concern.
Recommendation of the US
Preventive Services Task Force
The 2009 statement from the US Preventive Ser-
vices Task Force recommended against depres-
sion screening outside of integrated programs of
staff-assisted assessment and treatment. Evi-
dence from a recent meta-analysis19 of 11 trials
in primary care settings supports this recom -
mend ation. Although several of the trials found
that screening increased identification or treat-
ment of depression, none found that screening
reduced the number of patients with depression
or im proved depressive symptoms, and the over-
all ef fect estimate was virtually zero (standard-
ized mean difference [SMD] –0.02, 95% confi-
dence interval [CI] 0.25–0.20).
In contrast to the guidelines issued by the
National Institute for Health and Clinical Excel-
lence,7 the US Preventive Services Task Force
called for depression screening in primary care
where supports are in place to ensure appropriate
diagnosis, treatment and  follow-up.6 This recom-
mendation was based on results from four trials,
all of which found that patients with depression
who were provided staff-assisted programs for the
management of their condition had statistically
significantly better outcomes than patients who
did not receive such an intervention. An earlier
meta-analysis of more than 30 trials estimated that
interventions that in volve collaborative care sig-
nificantly reduce the symp toms of depression,
even if the effect is not large (SMD 0.25, 95% CI
0.18–0.32).20
Evidence evaluating whether screening for
depression is effective should be distinguished
from evidence evaluating whether interventions
that involve collaborative care to treat depression
improve outcomes over routine care. Indeed, of
the four trials cited by the US Preventive Services
Task Force as evidence supporting screening,
none actually evaluated screening. In each of the
four studies, patients were required to have de -
pressive symptoms or a diagnosis of depression to
be eligible for the trial. Patients with depression in
Analysis
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the intervention groups received collaborative care
for depression, whereas those in the control
groups received only standard care. Thus, whereas
the results of the trials suggest that providing col-
laborative care to patients with depression is better
than not providing such care, they do not address
whether screening would benefit patients with
previously unrecognized depression. Underlining
this point, among the three largest studies cited by
the task force (studies involving > 100 patients),
44% of patients in one trial were given treatment
for depression before their enrolment,21 and 44%
of patients in another of the studies were receiving
appropriate care for depression, defined as spe-
cialized counselling or treatment using antidepres-
sant medication, before their enrolment;22 data on
pretrial rates of treatment were not provided in the
third of these studies, but patients who were
already receiving treatment were not excluded
from the trial.23
There appears to be only one documented
attempt to screen and provide collaborative care
for depression in a clinical setting.24 In this study,
1687 patients deemed to be at high risk of
depression were sent a screening questionnaire.
The patients were invited to participate in the
study (completing and returning the question-
naire) via a letter signed by their general practi-
tioner, and a reminder was sent to nonresponders
two weeks later. Of the 1687 patients identified,
780 returned the screening questionnaire, 226 of
whom had a positive result (28.9%). A total of
173 patients with positive screening results were
assessed via a diagnostic interview, and 71 pa -
tients with major depression were detected. Of
these patients, 36 were already having their de -
pression treated and 18 declined treatment or did
not attend their appointment. Thus, only 1.0%
(17 of 1687) of patients eligible for screening
started treatment for their depression. Put an -
other way, about 100 people had to be invited to
be screened for 1 person to receive treatment for
depression. Based on a published estimate that
about one in seven patients receiving treatment
in primary care will do better than those not re -
ceiving treatment,25 about 700 people would need
to be approached for screening for one patient to
improve clinically. These results highlight the
potential resource implications of screening for
depression.
Can we assume that screening will
benefit patients?
We know of no clinical trial in which patients
screened for depression had better outcomes than
patients who were not screened when the same
re sources for treatment were available to both
groups, as would be the case in primary care set-
tings. Should we nonetheless assume that routine
screening would benefit patients? Several factors
argue against that  assumption.
Screening can generally only succeed to the
degree that it identifies patients whose condition
is otherwise unrecognized and untreated. Yet,
prescription rates for antidepressant medications
are already high and are trending upward.26
Among adults 35 years of age and older in the
US, annual rates of use for antidepressant medi -
ca tions increased from 8.3% to 14.1% from 1996
to 2005, with one-third to one-half of prescrip-
tions specifically for psychiatric problems.26 In a
2005 study from Canada, 7% of a sample of the
general population reported current use of anti-
depressant medications, a higher figure than the
estimated prevalence of major depression (4%).27
Rates of prescriptions for antidepressant medica-
tions may be even higher among patients with
long-term diseases. In Ontario, the rate of prescrip-
tions for antidepressant medications among pa -
tients aged 65 years and older within six months of
having an acute myocardial infarction doubled
from 8% in 1993 to 16% in 2002.28
Beyond treatment with antidepressant medica-
tions, province-wide data from Quebec show that
23% of women and 19% of men who consulted a
physician in 2003 received a diagnostic billing
code covering a depression or anxiety disorder at
some point during the year.29 Indeed, as the fre-
quency of recognition and treatment in creases,
the yield of screening interventions will decrease.
A consequence of the increasing rate of treat-
ment for depression is that existing studies ap -
pear to exaggerate the accuracy of screening
questionnaires and the number of otherwise un -
recognized patients who would be identified
through screening. A recent overview evaluated
original studies on the accuracy of depression
screening tools that were included in 17 system-
atic reviews or meta-analyses published from
2005 to 2009.30 The authors found that 189 of
197 original studies in those reviews (95.9%) in -
cluded patients with depression that had already
been diagnosed or was being treated. Screening,
however, is intended to identify new cases.
Including patients whose depression has already
been diagnosed or treated in studies of screening
tools exaggerates the ability of the tools to iden-
tify new cases and the number of people who
would start treatment as a result of the screening
process. Indeed, the authors of the overview esti-
mated that the number of patients with untreated
depression who would actually be detected by
screening may be less than half the number pre-
dicted by existing studies.
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In addition, the authors concluded that more
than 80% of positive screening results are likely
false-positives in primary care settings. This esti-
mate was based on published estimates of sensi-
tivity (85%) and specificity (74%) in primary
care31 and a 10% prevalence of major depres-
sion,32 conservatively assuming that 50% of
cases in actual practice are recognized without
screening33,34 and that published sensitivity fig-
ures are overestimated by 10% owing to the in -
clusion of patients whose condition has already
been diagnosed or treated.30 Thus, when used to
identify patients whose condition is undetected
and untreated, screening tools may be much less
accurate than is usually assumed. Compounding
this problem, no studies have estimated the
cumu lative false-positive rate from periodic
screening for depression in primary care, which
would certainly be very high.
Recent evidence raises questions about the
degree to which standard treatments for depres-
sion may benefit patients who are identified
through screening, but whose condition is not
obvious enough for them to seek help or be oth-
erwise identified. Recent meta-analyses have
reported that the effects of antidepressant med-
ications are smaller than previously believed
when all studies, rather than just published stud-
ies, are included (74 studies, SMD 0.31, 95% CI
0.27–0.35).35 In addition, when compared with
patients who receive a placebo, patients with mi -
nor depression or mild symptoms of major de -
pression receive much less benefit, if any, from
treatment with antidepressant medications than
patients with more severe symptoms.36–40
There is less evidence specific to primary care
settings; however, results generally appear to be
similar,25 despite the potentially increased hetero-
geneity and lower severity of depression in these
settings. Consequently, the UK guidelines7 rec-
ommend against using antidepressant medica-
tions as a first-line therapy for mild depression in
primary care, citing a poor risk–benefit ratio. Psy-
chotherapy is used much less frequently than
drug therapy in primary care settings, but esti-
mated effectiveness was generally similar to drug
therapies when considering only studies that met
minimum quality criteria in eight areas (11 trials,
SMD 0.22, 95% CI 0.13–0.31)41 or accounting
for likely publication bias (117 trials, SMD 0.42,
95% CI 0.33–0.51).42 Authors of a recent meta-
analysis43 found that, in primary care, psychologi-
cal treatments were effective when patients were
referred by their primary care physician (SMD =
0.43, 95% CI 0.28 to 0.58), but not when patients
were recruited through screening (SMD = 0.13,
95% CI -0.08 to 0.34). As with antidepressant
medications, there is evidence that psychological
treatments may be less effective for patients with
only mild symptoms of depression.44
What harm does screening pose?
In the absence of any benefit, potential harms of
screening for depression should be carefully con-
sidered, but the relevant information has rarely
been reported in trials. An important considera-
tion is the overall efficiency of screening and the
cost of adopting screening programs. At a mini-
mum, the costs of introducing screening into a
health care system that is already struggling
financially and is unable to effectively address
cases of depression that have already been identi-
fied would be substantial. Transferring resources to
screening activities could lead to a deterioration of
the quality of care received by patients with more
severe depression who are more clearly in need. In
addition, patients who are prescribed antidepres-
sant medications after a positive result from
screening, many of whom will not benefit from the
treatment, would be unnecessarily exposed to
common side effects of the drugs.
In addition, we know little about the potential
“nocebo effect” of telling patients who are other-
wise not specifically concerned about their men-
tal health that they have depression. A nocebo
effect is the opposite of a placebo effect, in that
verbal suggestions of a negative outcome can
lead to the development or worsening of symp-
toms.45 The two primary mechanisms underlying
nocebo are conditioning and expectations, and it
is possible that both could play a role in linking a
message from a physician about depression to
subsequent thoughts and behaviour.46
Conclusion
The prevalence of depression and the availability
of easy-to-use screening instruments make it
tempting to endorse widespread screening for the
disease. However, screening in primary care is a
resource-intensive endeavour, does not yet show
evidence of benefit and would have unintended
negative effects for some patients. Evidence from
one simulation study using Canadian national data
found that the overall burden of depression could
be reduced by providing more consistent treat-
ment to reduce symptoms and prevent relapse
among people with recurrent disorders, but not by
increasing treatment through screening.47
We hope that a rigorous review of current evi-
dence will encourage the developers of future
guidelines, including members of the Canadian
Task Force on Preventive Health Care, to carefully
consider their stance on screening for depression.
We also hope that, consistent with the 2010 guide-
Analysis
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lines of the National Institute for Health and Clini-
cal Excellence, such developers will conclude that
evidence from well-conducted, randomized, con-
trolled trials of the benefit of screening, in excess
of its likely harms and costs, is needed before it
can be recommended in primary care settings.
Specifically, the benefits and harms of screening
should be tested in a trial in which all patients
identified as having depression should have access
to the same integrated care for their condition,
regardless of whether they are identified through
screening in the intervention group or via physi-
cian recognition and referral in a control group. It
is possible that such a trial would find that screen-
ing benefits patients to a degree that would justify
the cost and the harms associated with the process.
Until then, however, given the lack of evidence of
benefit from screening and the concerns that we
have described, it is not reasonable to simply
assume that depression screening is good policy.
References
1. Canadian Task Force on the Periodic Health Examination. Early
detection of depression. In: The Canadian guide to clinical pre-
ventive health care. Ottawa (ON): Health Canada; 1994. p. 450-4.
2. US Preventive Services Task Force. Screening for depression.
In: Guide to clinical preventive services: Report of the US Pre-
ventive Services Task Force. 2nd ed. Washington (DC): US
Department of Health and Human Services; 1996. p. 541-6.
3. US Preventive Services Task Force. Screening for depression: Rec-
ommendations and rationale. Ann Intern Med 2002;136:760-4.
4. MacMillan HL, Patterson CJ, Wathen CN, et al. Screening for
depression in primary care: recommendation statement from the
Canadian Task Force on Preventive Health Care. CMAJ 2005;
172:33-5.
5. Katon WJ, Seelig M. Population-based care of depression: Team
care approaches to improving outcomes. J Occup Environ Med
2008; 50:459-67.
6. U.S. Preventive Services Task Force. Screening for depression in
adults: US Preventive Services Task Force recommendation
statement. Ann Intern Med 2009;151:784-92.
7. National Collaborating Center for Mental Health. The NICE
guideline on the management and treatment of depression in
adults (updated edition). London (UK): National Institute for
Health and Clinical Excellence; 2010.
8. McLachlan SA, Allenby A, Matthews J, et al. Randomized trial of
coordinated psychosocial interventions based on patient self-
assessments versus standard care to improve the psychosocial
functioning of patients with cancer. J Clin Oncol 2001;19:4117-25.
9. UK National Screening Committee. Second report of the UK
National Screening Committee. London (UK): Departments of
Health for England, Scotland, Northern Ireland and Wales; 2000.
10. Raffle A, Gray M. Screening: evidence and practice. London
(UK): Oxford University Press; 2007.
11. Mojtabai R, Olfson M. National patterns in antidepressant treat-
ment by psychiatrists and general medical providers: results
from the National Comorbidity Survey replication. J Clin Psy-
chiatry 2008;69:1064-74.
12. Fernández A, Haro JM, Martinez-Alonso M, et al. Treatment
adequacy for anxiety and depressive disorders in six European
countries. Br J Psychiatry 2007;190:172-3.
13. Wilson JM, Jungner G. Principles and practices of screening for
disease. Geneva (Switzerland): World Health Organization; 1968.
14. Shakespeare J. Evaluation of screening for postnatal depression
against the NSC handbook criteria. London (UK): UK National
Screening Committee; 2001.
15. Palmer SC, Coyne JC. Screening for depression in medical care:
Pitfalls, alternatives, and revised priorities. J Psychosom Res
2003; 54:279-87.
16. Gilbody S, Sheldon T, Wessely S. Should we screen for depres-
sion? BMJ 2006;332:1027-30.
17. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening
and patient outcomes in cardiovascular care: a systematic re -
view. JAMA 2008;300:2161-71.
18. Paulden M, Palmer S, Hewitt C, et al. Screening for postnatal
depression in primary care: cost effectiveness analysis. BMJ
2009;339:b5203.
19. Gilbody S, Sheldon TD, House AD. Screening and case-finding
instruments for depression: a meta-analysis. CMAJ 2008; 178:
997-1003.
20. Gilbody S, Bower P, Fletcher J, et al. Collaborative care for
depression: a cumulative meta-analysis and review of longer-
term outcomes. Arch Intern Med 2006;166:2314-21.
21. Rost K, Nutting PA, Smith J, et al. Designing and implementing
a primary care intervention trial to improve the quality and out-
come of care for major depression. Gen Hosp Psychiatry 2000;
22: 66-77.
22. Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of dis-
seminating quality improvement programs for depression in
managed primary care: A randomized controlled trial. JAMA
2000; 283:212-20.
23. Rubenstein LZ, Alessi CA, Josephson KR, et al. A randomized
trial of a screening, case finding, and referral system for older
veterans in primary care. J Am Geriatr Soc 2007;55:166-74.
24. Baas KD, Wittkampf KA, van Weert HC, et al. Screening for
depression in high-risk groups: prospective cohort study in gen-
eral practice. Br J Psychiatry 2009;194:399-403.
25. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus
placebo for depression in primary care [review]. Cochrane
Database Syst Rev 2009;(3):CD007954.
26. Olfson M, Marcus SC. National patterns in antidepressant med-
ication treatment. Arch Gen Psychiatry 2009;66:848-56.
27. Esposito E, Wang JL, Adair CE, et al. Frequency and adequacy
of depression treatment in a Canadian population sample. Can J
Psychiatry 2007;52:780-9.
28. Benazon NR, Mamdani MM, Coyne JC. Trends in the prescrib-
ing of antidepressants following acute myocardial infarction,
1993-2002. Psychosom Med 2005;67:916-20.
29. Tannenbaum C, Lexchin J, Tamblyn R, et al. Indicators for mea-
suring mental health: towards better surveillance. Healthc Policy
2009;5:e177-86.
30. Thombs BD, Arthurs E, El-Baalbaki G, et al. Risk of bias from
inclusion of patients who already have a diagnosis or are under-
going treatment for depression in diagnostic accuracy studies of
screening tools for depression: systematic review. BMJ 2011;
343: d4825.
31. Williams JW Jr, Pignone M, Ramirez G, et al. Identifying
depression in primary care: A literature synthesis of case-finding
instruments. Gen Hosp Psychiatry 2002;24:225-37.
32. O’Connor EA, Whitlock EP, Beil TL, et al. Screening for
depression in adult patients in primary care settings: a system-
atic evidence review. Ann Intern Med 2009;151:793-803.
33. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in
primary care: a meta-analysis. Lancet 2009;374:609-19.
34. Tiemens BG, VonKorff M, Lin EH. Diagnosis of depression by
primary care physicians versus a structured diagnostic interview.
understanding discordance. Gen Hosp Psychiatry 1999;21:87-96.
35. Turner EH, Matthews AM, Linardatos E, et al. Selective publi-
cation of antidepressant trials and its influence on apparent effi-
cacy. N Engl J Med 2008;358:252-60.
36. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity
and antidepressant benefits: A meta-analysis of data submitted to
the Food and Drug Administration. PLoS Med 2008;5:e45.
37. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant
drug effects and depression severity: a patient-level meta -
analysis. JAMA 2010;303:47-53.
38. Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants
and benzodiazepines in minor depression: systematic review and
meta-analysis. Br J Psychiatry 2011;198:11-6.
39. Khan A, Leventhal RM, Khan SR, et al. Severity of depression
and response to antidepressants and placebo: an analysis of the
Food and Drug Administration database. J Clin Psychopharmacol
2002;22:40-5.
40. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of effi-
cacy data from major depressive disorder trials submitted to the
US Food and Drug Administration in support of new drug appli-
cations. J Clin Psychiatry 2011;72:464-72.
41. Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of
psychotherapy for adult depression are overestimated: A meta-
analysis of study quality and effect size. Psychol Med 2010; 40:
211-23.
42. Cuijpers P, Smit F, Bohlmeijer E, et al. Efficacy of cognitive-
behavioural therapy and other psychological treatments for adult
depression: Meta-analytic study of publication bias. Br J Psychiatry
2010;196:173-8.
43. Cuijpers P, van Straten A, van Schaik A, et al. Psychological treat-
ment of depression in primary care: a meta-analysis. Br J Gen Pract
2009;59:e51-60.
Analysis
CMAJ, March 6, 2012, 184(4) 417
44. Driessen E, Cuijpers P, Hollon SD, et al. Does pretreatment
severity moderate the efficacy of psychological treatment of
adult outpatient depression? A meta-analysis. J Consult Clin
Psychol 2010;78:668-80.
45. Benedetti F, Lanotte M, Lopiano L, et al. When words are
painful: unraveling the mechanisms of the nocebo effect. Neuro-
science 2007;147:260-71.
46. Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo
groups in antidepressant trials. Philos Trans R Soc Lond B Biol
Sci 2011;366:1879-88.
47. Patten SB. A framework for describing the impact of antidepres-
sant medications on population health status. Pharmacoepi-
demiol Drug Saf 2002;11:549-59.
Affiliations: From the Departments of Psychiatry; Medicine;
Epidemiology, Biostatistics, and Occupational Health; and
the School of Nursing (Thombs), McGill University and
Lady Davis Institute for Medical Research, Jewish General
Hospital, Montréal, Que.; Behavioral Oncology Program
(Coyne), Abramson Cancer Center and Department of Psy-
chiatry, University of Pennsylvania School of Medicine,
Philadelphia, Pa.; Health Psychology Section, Department of
Health Sciences (Coyne), University Medical Center Gronin-
gen, University of Groningen, the Netherlands; the Depart-
ment of Clinical Psychology and EMGO Institute (Cuijpers),
Vrije Universiteit, Amsterdam, the Netherlands; Interdiscipli-
nary Center for Psychiatric Epidemiology (de Jonge), Uni-
versity Medical Center, University of Groningen, Groningen,
the Netherlands; Psychological Medicine and Health Ser-
vices Research (Gilbody), Hull York Medical School and
Department of Health Sciences, University of York, York,
UK; Clinical and Molecular Epidemiology Unit (Ioannidis),
Department of Hygiene and Epidemiology, University of
Ioannina School of Medicine, and Biomedical Research
Institute, Foundation for Research and Technology–Hellas,
Ioannina, Greece; Institute for Clinical Research and Health
Policy Studies (Ioannidis), Tufts Medical Center, and Depart-
ment of Medicine, Tufts University School of Medicine,
Boston, Mass.; Stanford Prevention Research Center (Ioanni-
dis), Stanford University School of Medicine, Stanford,
Calif.; the Department of Psychology and Center for Health,
Intervention and Prevention (Johnson), University of Con-
necticut, Storrs, Conn.; the Departments of Psychiatry and
Community Health Sciences (Patten), University of Calgary,
Calgary, Alta.; the Department of Psychiatry (Turner), Ore-
gon Health and Science University and Portland Veterans
Affairs Medical Center, Portland, Ore.; the Department of
Medicine (Ziegelstein), Johns Hopkins University School of
Medicine, Baltimore, Md.
Contributors: Dr. Thombs drafted the article. All of the
authors participated in preliminary discussions to develop the
concepts described in the article, agreed upon an outline for
the article, revised the article critically for intellectual content
and approved the final version of the manuscript submitted
for publication.
Funding: Funds from a Meetings, Planning and Dissemina-
tion grant from the Canadian Institutes of Health Research
(CIHR; grant no. MIN 92725) were used for a meeting of the
author group, which led to the preparation of this article. Dr.
Thombs is supported by a New Investigator Award from the
CIHR and an Établissement de Jeunes Chercheurs award
from the Fonds de la Recherche en Santé Québec. Dr. Patten
is a Senior Health Scholar with Alberta Innovates, Health
Solutions. Dr. Ziegelstein is supported by the National Center
for Complementary and Alternative Medicine (grant no.
R24AT004641) and the Miller Family Scholar Program of
the Johns Hopkins Center for Innovative Medicine. The con-
tent is solely the responsibility of the authors and does not
necessarily represent the official views of the National Center
For Complementary and Alternative Medicine or the National
Institutes of Health.
Analysis
418 CMAJ, March 6, 2012, 184(4)
We have partnered with Sheridan Press!
To purchase commercial article reprints and
e-prints or to request a quote, please contact 
Matt Neiderer
Content Sales 




























































































































































































   
 
                                     
 































































































ty for Vascular 
Surgery
Canadian Socie



























of care and mo
rtality following




tions of a 
clinical research














































































































































and pulmonary embolism 
PRACTICE
HPV and anogenital warts 
in children
medical knowledge that matters
CMAJ•JAMC
FEBRUARY 21, 2012, VOL. 184 (3)
WWW.CMAJ.CA
REPRINTS
800 635-7181 x6265 
matt.neiderer@sheridan.com 
Copyright of CMAJ: Canadian Medical Association Journal is the property of Canadian Medical Association
and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright
holder's express written permission. However, users may print, download, or email articles for individual use.
